Dendreon Corp (NASDAQ:DNDN)

Money background. Close-up.

The Shame and Lessons of a Dendreon Bankruptcy

Dendreon Corp. (NASDAQ: DNDN) has committed the ultimate sin by filing for bankruptcy protection. This should not be a total surprise as it was in August that we warned that ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: Dendreon, Facebook, Google, Home Depot, Twitter, WisdomTree and More

Stocks were indicated to be marginally lower on Monday, but not so much that the direction of the day looked certain. What we saw in October, even during the sell-off ...
Read Full Story »
biotech

Credit Suisse Positive on Some Biotechs, Very Cautious on Others

Credit Suisse has launched new biotech coverage on Wednesday with two analysts at the firm. The biotech sector has been a wealth-creation engine in recent years. What is interesting here ...
Read Full Story »
153790263

Is an Impending Implosion of Dendreon Avoidable?

Dendreon Corp. (NASDAQ: DNDN) has turned into one of those unsettling biotech stories: It went from great promise, to high hopes, to a reality check, and now to an incredibly ...
Read Full Story »
ten bucks

Ten Analyst Stocks to Buy Under $10 for Big Upside

Earnings season is winding down and the markets remain choppy. Investors are wary, but they want upside and they keep hearing that this is now a stock picker's market. 24/7 ...
Read Full Story »
145922793

Will the Last Interested Person in Dendreon Turn Out the Lights?

Dendreon Corp. (NASDAQ: DNDN) is getting crushed, and the share price is down to levels not seen in a decade. The company's reported Provenge sales were again unimpressive. What is ...
Read Full Story »
biotech

Companies Betting on the Next 10 Blockbuster Drugs

The biotech sector has seen its valuations hit hard in many cases in 2014, but many investors remain excited about the future wave of big biotech drugs -- and big ...
Read Full Story »
Biotechnology word cloud

Who Bucked the Short Interest Trend in Biotech Stocks?

24/7 Wall St. has tracked the short interest in leading biotech and emerging pharmaceutical stocks. Many biotech stocks pulled back in late March, and short sellers moved in on many ...
Read Full Story »
Biotechnology word cloud

Short Sellers Find Renewed Interest in Biotech Stocks

24/7 Wall St. has tracked the short interest in leading biotech and emerging pharmaceutical stocks. After retreating from many of these stocks in the previous two periods, short sellers returned ...
Read Full Story »
Biotechnology word cloud

Short Sellers Retreat From Biotech Stocks Again

24/7 Wall St. has tracked the short interest in leading biotech and emerging pharmaceutical stocks. Stocks in this industry continue to be hot, but short sellers shied away from many ...
Read Full Story »
DNA

Analyst Still Sees Dendreon Worth Only $1

Dendreon Corp. (NASDAQ: DNDN) remains a company in trouble. The post-earnings jump looked promising and investors probably took some comfort when shares popped from $2.88 up to $3.31. Unfortunately, that ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: Cliffs, Dendreon, Magna, Santander, SunEdison and More

Stocks are trying to stage a post-Ukraine recovery on Tuesday. This week only reminds most investors that, even if the markets keep challenging new highs, they may have to protect ...
Read Full Story »
DNA

Dendreon Finds New, Long Overdue Lifeblood

Shares of Dendreon Corp. (NASDAQ: DNDN) moved higher Monday after the biotech company said it will start to market Provenge, its prostate-cancer drug, in Europe this year. The announcement came ...
Read Full Story »
Biotechnology word cloud

Short Sellers Return to Biotech Stocks

24/7 Wall St. has tracked the short interest in leading biotech and emerging pharmaceutical stocks. After largely shying away in the previous period, short sellers returned to many of these ...
Read Full Story »
Biotechnology word cloud

Short Sellers Shy Away From Biotechs

24/7 Wall St. has tracked the short interest in leading biotech and emerging pharmaceutical stocks. By and large, short sellers shied away from these stocks in late January. The largest ...
Read Full Story »